Results 181 to 190 of about 163,661 (247)

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). [PDF]

BMJ Open
Ozaki Y, Koyama S, Morita S, Miyashita M, Tokuda E, Shimoi T, Fukuoka M, Masuda H, Takano Y, Shibata N, Yoshinami T, Murakami A, Tamaki K, Ishiguro H, Saji S, Miwa A, Matsunaga J, Zheng Y, Nishikawa H, Masuda N.   +19 more
europepmc   +1 more source

Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. [PDF]

Signal Transduct Target Ther
Zhang X, Wei J, Chen N, Liu K, Liang R, Ma L, Song Z, Gu X, Chen X, Yang S.   +9 more
europepmc   +1 more source

Genome-Wide Analysis of <i>bZIP</i> Transcription Factors and Expression Patterns in Response to Shading Treatment in <i>Taxus yunnanensis</i>. [PDF]

Curr Issues Mol Biol
Fan J, Gong P, Liu Y, Dou M, Li Q, Hu Q, Wang Y, Wang G, Huang X.   +8 more
europepmc   +1 more source

Can Wapiti (Cervus elaphus) Browsing Stimulate the Chemical Defense of Taxus cuspidata—A Case of Northeast China Tiger and Leopard National Park

Integrative Zoology, EarlyView.
We study that browsing by wapiti reduces the growth of saplings, and it develop chemical defenses to prevent themselves browsed again. These results reduce our concern about wapiti browse T. cuspidate saplings, and provide basic data for the study of the interaction between them, and also provide theoretical basis for the population restoration and ...
Jianan Feng, Hairong Du, Xianzhe Wang, Minghai Zhang   +3 more
wiley   +1 more source

Therapeutic Efficacy of Nanodrug Delivery Compared With Current Nonsurgical Treatments for Patients With Cutaneous Melanoma: A Systematic Review. [PDF]

Cureus
Hussain Z, Buhaimed N, Al Khalifa M, Aljalahma J, Alomran B.   +4 more
europepmc   +1 more source

GLUT3 drives paclitaxel resistance in peritoneal metastatic gastric cancer by promoting H3K18 lactylation-mediated MAPKAP1 transcription to suppress ferroptosis. [PDF]

Int J Biol Sci
Sun Y, Duan X, Zhang B, Xiong C, Ji J, Cai Q, Yao W, Jiang J, Wu J, Wang C, Guo L, Zhou C, Yu B, Qi F, Zhang J.   +14 more
europepmc   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. [PDF]

Signal Transduct Target Ther
Cao Z, Qiu J, Luo W, Li J, Chen H, Liu Y, Li S, Li F, Yang Y, Cheng Y, Zhang T, Xue H, Bai C, Zhao Y.   +13 more
europepmc   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source